Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
FATE(NASDAQ:FATE) SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on September 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 45,000 shares of the Company’s common stock at an exercise price per share of $1.03, which was the closing price per share of the Company’s common stock as reported by NASDAQ on September 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 63,000 shares of its common stock to two newly-hired non-executive employees, including the newly-hired employee receiving the non-qualified stock options referenced above. The grants were approved by the Compensation Committee of the Company’s Board of Directors and